1) What is RetmarkerAMD Research?
RetmarkerAMD Research allows for the digital marking of images from patients with Age-related Macular Degeneration (AMD), the main reason of blindness in persons over 50 years old in developed countries.
RetmarkerAMD Research was developed for an Epidemiological Study and makes use of Retmarker’s image exploration features and adds manual and preset annotation of Drusen (including confluence), Hypopigmentation, Hyperpigmentation, Geographic Atrophy and Exudative Lesions.
RetmarkerAMD Research automatically counts lesions (in number and area) by lesion type and location (sub-field), significantly reducing the time needed.
RetmarkerAMD simplifies the diagnostic by ophthalmologists, as they now have a more precise source of information, which is not prone to errors related to the complexity in the estimations of lesion areas present in each region of the colour fundus photographs.
2) Why is RetmarkerAMD Research relevant?
"This new tool allows for a faster and more precise way to conduct a detailed analysis of the lesions associated the early and late forms of Age-related Maculopathy. It promotes the creation of a broad basis for the assertive discussion on the prognostic value of the different lesions found in this disease", underlines Professor Rufino Silva, a respected expert from AIBILI and the Coordinator of Section for the Retina and Vitreous of the Portuguese Ophthalmology Society, who has been contributing towards the development of this solution together with Professor José Rui Faria de Abreu and Maria da Luz Cachulo M.D..
From an Information Technology point of view, RetmarkerAMD Research won an award in the European IT Excellence Awards 2010, an event which gathered in London the leading organizations in this area.
3) What about Drusen Turnover or any other research topics?
At the current moment both RetmarkerAMD Research and RetmarkerC can be used in AMD patients and together they can be used to help evaluating each patient and monitor how they progress over time.
RetmarkerAMD Research has a semi-automated tool to compare different exams from the same patient. Such tool is very useful to compare manual marked lesions in different image modalities and also to quantify the evolution of manually marked lesions over time (per image region).
We believe that biomarker concepts similar to what there is already for Diabetic Retinopathy (the Microaneurysm Turnover) will appear in the next years for AMD and we are actively working to develop software solutions that address this trend.
If you have a specific need or wish to perform any research project related to this matters, please feel free to contact us using the available Contacts form.
4) Does RetmarkerAMD Research performs diagnosis?
No! Doctors perform diagnosis and define treatments.
RetmarkerAMD Research does not even perform any automated detection for the time being.
5) With which images and conditions does RetmarkerAMD Research works?
While Retmarker was developed for colour fundus photographs, centered on the retina’s posterior pole, with the optic disc visible (field 2 images) it does support other type of images such as Red Free, Infra Red, Angiography, etc., provided that the optic disc is visible.
6) I still have doubts regarding the Retmarker product family... Who can I talk to?
If you have any additional doubts, please feel free to contact us using the Contacts form available.